BladderBoneBrainBreastCervicalColonEsophagealKidneyLaryngealLeukemia CancerLiverLungLymphomaMouthOvarianPancreaticProstateRectalSkinTesticularThroatUterinePress, Medical / Health ReportingBladder CancerBone CancerBrain CancerBreast CancerCervical CancerColon CancerEsophageal CancerKidney CancerLaryngeal CancerLeukemiaLiver CancerLung CancerLymphoma CancerMouth CancerOvarian CancerPancreatic CancerProstate CancerRectal CancerSkin CancerTesticular CancerThroat CancerCancerUterine CancerHealth TechnologyMedical Reporting
Updated on May 26, 2022
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:
More Answers Needed About Relocation of Former Cruise Ship Passengers: Judge
Federal and California officials must provide more information to local officials about plans to relocate former cruise ship passengers who've tested positive for the new coronavirus to a facility in a Southern California community, a federal judge ruled Monday.
Officials in the city of Costa Mesa oppose the transfer to their community of coronavirus patients who were evacuated from a cruise ship in Japan, the Associated Press reported.
Mistakes can be made when acting in haste, said U.S District Judge Josephine Staton, who'd already temporarily blocked federal officials from transferring passengers to the site. She scheduled another hearing next Monday to review the issue.
Passengers who were evacuated from the cruise ship are under quarantine at Travis Air Force Base in Northern California. Those who tested positive for the new coronavirus were sent to area hospitals but can't be returned to Travis once they no longer need treatment, according to federal officials.
However, Costa Mesa officials said they weren't included in the planning process and want to know why a facility recently deemed too dilapidated for a homeless shelter is suddenly being considered to house those passengers, the AP reported.
"There's just something not right, and we have to question that, because the information that we're being given is not credible," Costa Mesa Mayor Katrina Foley told the media after Monday's hearing.
Purdue Launches Ad Campaign for OxyContin Claims
An ad campaign to inform people harmed by the prescription opioid OxyContin as to where they can file claims against maker Purdue Pharma was launched Monday by the company, as part of bankruptcy proceedings.
Notifying those who may have claims against a company is standard in bankruptcies, and Purdue is seeking to resolve close to 3,000 lawsuits over its role in the U.S. opioid crisis, the Associated Press reported.
The $23.8 million ad campaign from the Stamford, Conn.-based company was developed with input from a committee of creditors and other interested parties, and approved by a bankruptcy judge.
Purdue has proposed a settlement that could eventually be worth more than $10 billion, including the value of drugs it's making and a contribution of at least $3 billion in cash from the Sackler family, which owns the company, the AP reported.
New Cholesterol Drug Approved by FDA
A new type of cholesterol-lowering drug that works differently than statins has been approved by the U.S. Food and Drug Administration.
Esperion Therapeutics Inc.'s Nexletol will provide an alternative for people who can't tolerate or don't fully respond to statins such as Lipitor and Crestor, the Associated Press reported.
Nexletol is a daily pill approved for people with a genetic predisposition for high cholesterol and for heart disease patients who need to further reduce their bad cholesterol. The drug is to be taken at the highest dose patients can tolerate and used in conjunction with a healthy diet, according to the FDA.
"This is a nice alternative" to statins, but statins will still be the first choice, Dr. Christie Ballantyne, Baylor College of Medicine's cardiology chief, told the AP. He consults for Esperion and helped test Nexletol.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Read this Next
Other Trending Articles